Trials / Completed
CompletedNCT00232102
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 423 (planned)
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod |
Timeline
- Start date
- 2004-09-01
- Completion
- 2006-08-01
- First posted
- 2005-10-04
- Last updated
- 2008-02-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00232102. Inclusion in this directory is not an endorsement.